Prophylaxis glycopyrolate reduce cardiovascular effects from propofol and reduce salivary during change position in open urologic patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200910001

Enrollment

Unknown

Registered

2020-09-10

Start date

2018-12-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ASA I&#45

Interventions

Group G have given glycopyrrolate 0.1 mg injection 5&#44

3 min after start doses of propofol. Blood pressure&#44

heart rate and salivary volume were measured.,Group C have given nss 0.5 ml injection 5&#44

heart rate and salivary volume were measured.

Active Comparator Drug,Placebo Comparator Genetic

glycopyrolate 0.2 mg (1 ml.),normal saline 1 ml.

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: ASA I-II Elective nephrolithotomy and ureterolithotomy and nephrectomy surgery patients

Exclusion criteria

Exclusion criteria: glaucoma, prostatic hypertrophy, hyperthyroid, cardiovascular disease, pulmonary disease, morbid obesity, renal or hepatic dysfunction, neuromuscular disease, premedication used in sugery day

Design outcomes

Primary

Measure	Time frame
efficacy of glycopyrrolate during induction and intubation phase for anesthesia cardiovascular effect,efficacy of glycopyrrolate during induction and intubation phase for anesthesia salivary volume	—

Secondary

Measure	Time frame
cardiovascular effect during induction and intubation phase for anesthesia blood presure, heart rate	—

Countries

Thailand

Contacts

Public ContactKamoltip Prasopsook

Sawanpracharak Hospital

kamolkate@hotmail.com0869231384

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026